New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.

Katarzyna B HooksJérôme AudouxHelena FazliSarah LesjeanTony ErnaultNathalie Dugot-SenantThierry Leste-LasserreMartin HagedornBenoit RousseauCoralie DanetSophie BranchereauLaurence BrugièresSophie TaqueCatherine GuettierMonique FabreAnne RullierMarie-Annick BuendiaThérèse CommesChristophe F Grosset Anne Aurélie Raymond

Published in: Hepatology (Baltimore, Md.) (2018)

The highly proliferating C2A subtype is characterized by topoisomerase 2-alpha gene up-regulation and FA pathway activation, and the HB therapeutic arsenal could include bortezomib for the treatment of patients with the most aggressive tumors. (Hepatology 2018;68:89-102).

Keyphrases

genome wide
copy number
gene expression
newly diagnosed
dna methylation
genome wide identification
transcription factor
replacement therapy